Novartis
Novartis targets GA gene therapy in Gyroscope Therapeutics deal
Novartis has announced it is acquiring Gyroscope Therapeutics, the UK-based company behind an investigational dry ADM gene therapy that is ...
Most pressing eye health issues raised with PM
The state of public cataract surgery and Indigenous eye health were among the key issues a delegation from the ophthalmic ...
Clinical trial results reinforce potential new treatment for DME
Novartis has announced positive findings from its the Phase 3 trial assessing the efficacy and safety of Beovu (brolucizumab) to ...
Only half of Australian diabetics getting recommended eye checks
As the KeepSight program hit 100,000 enrolments, a new University of Sydney study has found only half of diabetics are ...
TGA approves first pharma option for proliferative diabetic retinopathy
For 40 years laser therapy has been the standard treatment for proliferative diabetic retinopathy (PDR), but now Australian ophthalmologists have ...
TGA approves Luxturna gene therapy
In a historical development for the eye health sector, the Therapeutics Goods Administration (TGA) has approved the country’s first true ...
KeepSight registrations hit 80,000
Registrations with eye check reminder program KeepSight have surpassed 80,000, with enrolment rates now on the rise after dropping during ...
Drug developer hits major milestone with Lucentis biosimilar
A biopharmaceutical company that is developing cheaper anti-VEGF treatments for major global markets, including Australia, has reported positive results from ...
Novartis acquires gaming tech for ‘lazy eye’
Novartis is collaborating with video game developers and academics to develop digital technology to treat amblyopia following its completed acquisition ...